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Abstract: In recent years many data indicate that lymphocytes from cancer patients undergo increased apoptosis. The objective
of this study was to evaluate the expression of Fas receptor on lymphocytes obtained from patients with lung cancer. Eighteen
patients with non-small cell lung cancer and 18 healthy volunteers were investigated. Expression of Fas (CD95) on CD4+ and
CD8+ blood lymphocytes was evaluated by flow cytometry. The proportion of blood Fas+ lymphocytes was significantly
higher in lung cancer patients when compared with healthy individuals and in smokers when compared with nonsmokers.
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Introduction
The role of lymphocytes accumulated in the tumor envi-
ronment in the host defense against lung cancer is well
documented. Nevertheless, these defense mechanisms are
impaired and many recent data indicate that lymphocytes
from patients with malignancies undergo apoptosis [11].
One way of apoptosis signaling is the Fas-Fas ligand
(FasL) interaction [6]. It has been demonstrated that many
neoplastic cells express FasL [11] and can directly induce
death of activated Fas-positive lymphocytes [7]. The role
of cytotoxic CD8+ lymphocytes in immunology of lung
cancer was reported before [2]. An elevated proportion of
these cells in the bronchoalveolar lavage (BAL) of patients
with lung cancer was found, while the proportion of these
cells in the blood was lower [2]. The involvement of
apoptosis is possible in such changes of lymphocyte pro-
portions in patients. The aim of this study was to evaluate
the expression of Fas receptor on CD4+ and CD8+ lym-
phocytes obtained from peripheral blood of patients with
non-small cell lung cancer.
Materials and methods
Subjects. Eighteen patients with lung cancer (4 female and 14 male)
and 18 healthy volunteers (10 female and 8 male) were investigated.
The age of patients ranged from 37 to 81 yrs and of healthy persons:
from 30 to 76 yrs. All cancer patients were smokers (mean number
of pack-years - number of cigarette packs smoked per day multiplied
by the number of years of smoking - was 48±36) and there were 10
smokers (mean number of pack-years 32±36) and 8 nonsmokers in
the control group. 
In all patients, histological examination confirmed non-small cell lung
cancer - in 4 patients squamous cell type, in 1 - adenocarcinoma, and in
the others undifferentiated. There was 1 patient at stage 1, 3 were at stage
2, 6 at stage 3 and 8 at stage 4 of lung cancer. The study was approved by
the Ethics Committee of the Warsaw Medical School. All the healthy
volunteers signed an informed consent form. Subjects with any infection
or chronic pulmonary disease were excluded from the study. The persons
examined were not undergoing corticosteroid or immunosupressive ther-
apy one year before and at the time of the examination.
Flow cytometry analysis. The analysis of Fas expression was
performed on lymphocytes from the venous blood. The following
mixtures of antibodies were used for the cell phenotyping: anti-
CD45-FITC and anti-CD14-PE, negative isotype controls (Ig2a-
FITC and Ig2b-PE), anti-CD4-FITC and anti-CD95-PE,
anti-CD8-FITC and anti-CD95-PE (Becton-Dickinson Immunocy-
tometry Systems, San Jose, California). Two-color analysis of cells
was performed as described previously [4]. Anti-CD45-FITC and
anti-CD14-PE was used for the lymphocyte gate setting at FSC/SSC
graph. The samples were analyzed using a FACS Calibur flow
cytometer (Becton-Dickinson, San Jose, California). The cells were
collected by CELLQuest software.
Statistical analysis. Nonparametric Mann-Whitney U-test was ap-
plied with p<0.05 being regarded as significant. The relationship
between the proportion of cells and smoking history expressed as
pack-years was assessed by the Spearman correlation test.
Results and discussion
We found elevated proportion of lymphocytes with ex-
pression of Fas (CD95) in the peripheral blood of pa-
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Fig. 1. Flow cytometry profile of peripheral blood (PB) lymphocytes from: A - healthy person, B - patient with lung cancer. Left dot plots:
lymphocytes CD95+/CD4+ in the upper right quadrant; right dot plots: lymphocytes CD95+/CD8+ in the upper right quadrant.
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tients with non-small cell lung cancer when compared
with healthy persons. Table 1 shows the mean propor-
tion of Fas+ CD4+ lymphocytes as percentage of all
CD4+ lymphocytes and the proportion of Fas+ CD8+
lymphocytes as percentage of all CD8+ lymphocytes.
The proportion of Fas-positive CD4+ lymphocytes was
significantly higher in patients when compared to
healthy persons. The proportion of Fas-positive CD8+
lymphocytes was also significantly higher in patients
when compared to healthy persons. These differences
between patients and healthy persons were significant.
Figure 1 presents the representative examples of flow
cytometry assay of Fas-positive lymphocytes. In each
group, the proportion of Fas-positive CD4+ and Fas-
positive CD8+ lymphocytes were similar (Tab. 1). 
A significantly higher percentage of Fas-positive
lymphocytes was found in healthy smokers when com-
pared to healthy nonsmokers, however, the proportion
of Fas-positive lymphocytes in smokers with lung
cancer when compared to healthy smokers was still
higher (Tab. 2). A significant positive correlation was
found between proportion of Fas-positive lymphocytes
and smoking history expressed as pack-years (Fig. 2).  
 In this study we examined lymphocytes expressing
"death receptor" Fas derived from the peripheral blood
of patients with lung cancer. We have not found data on
this subject in the literature. The impairment of host
defense against cancer may result from depletion of
lymphocytes. One way of this depletion is apotosis of
lymphocytes after contact with tumor cells. It was do-
cumented that many tumor cells express Fas ligand
(FasL) and may induce apoptosis of Fas-positive lym-
phocytes [3, 9, 11, 13]. Little is known about the mech-
anisms of apoptosis of lymphocytes in the lung cancer
environment, the results presented by Niehans et al. [7]
suggested that lung cancer cell lines express functional
FasL and that lung cancer cells were capable of killing
T cells. We found a significantly higher proportion of
Fas-positive lymphocytes in the blood of patients with
lung cancer when compared with healthy individuals.
These findings are in agreement with the observations
in other types of neoplasms [3, 8, 9, 13]. We demon-
strated previously a significant depletion of peripheral
blood CD8+ in patients with lung cancer [2]. Saito et al.
[8] reported that mainly CD8+ cells undergo apototsis
Fig. 2. Correlation of proportion of
Fas-positive CD4+ lymphocytes in
the blood of smokers with smoking
history expressed as pack-years (PY)
(significant in Spearman test, R =
0.6, p<0.05).
Table 1. Expression of Fas (CD95) on peripheral blood (PB) lym-
phocytes in lung cancer patients and healthy individuals
Patients
n = 18
Healthy
n = 18
CD95+ CD4+a 86.5 ± 8.7* 63.9 ± 11.9*
CD95+ CD8+b 85.9 ± 9.1* 64.8 ± 14.9*
a
cells with expression of CD95 as percentage of all CD4+ cells
(mean ± SD)
b
cells with expression of CD95 as percentage of all CD8+ cells
(mean ± SD)
*p<0.05 in Mann Whitney U-test 
Table 2. Expression of Fas (CD95) on blood lymphocytes in smokers
and nonsmokers
Patients Healthy
smokers
n = 18
smokers
n = 10
nonsmokers
n = 8
CD95+ CD4+a 86.5 ± 8.7* 69.7 ± 8.1* 56.6 ± 12.2*
CD95+ CD8+b 85.9 ± 9.1* 72.1 ± 6.1* 55.7 ± 17.9*
a
cells with expression of CD95 as percentage of all CD4+ cells
(mean ± SD)
b
cells with expression of CD95 as percentage of all CD8+ cells
(mean ± SD)
*p<0.05 in Mann Whitney U-test 
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in melanoma, Hoffmann et al. [3] observed greater
proportion of apoptotic CD8+ cells in patients with head
and neck cancer. In this study, we did not find any
differences between the proportions of Fas+ CD8+ lym-
phocytes and Fas+ CD4+ cells in cancer patients. It
seems possible that other or more complex mechanisms
than Fas-FasL interaction are involved in blood CD8+
lymphocyte depletion in lung cancer. 
The main exogenous cause of lung cancer is tobacco
smoke. In this study we found elevated proportion of
Fas+ lymphocytes in smokers (both, patients and
healthy). The data on the influence of tobacco smoke on
lymphocyte apoptosis is very scarce. Bijl et al. [1] found
an increased expression of Fas on blood lymphocytes in
smokers, while Suzuki et al. [10] did not find any
differences in the expression of Fas on lymphocytes
between smokers and nonsmokers [10]. We observed
before an elevated proportion of activated lymphocytes
in the blood of smokers [5]. Fas is upregulated on
lymphocytes after their activation [12] what may explain
our present observation in smokers.
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